Cargando…
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
Atherosclerotic cardiovascular disease is a systemic condition involving several vascular districts. The most involved vascular bed, beyond the coronary district, is represented by the peripheral arteries, whose involvement can give rise to cerebrovascular or peripheral events. PCSK9 inhibitors (PCS...
Autores principales: | Cesaro, Arturo, Acerbo, Vincenzo, Raucci, Giuseppe, Calabrò, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653138/ https://www.ncbi.nlm.nih.gov/pubmed/36380810 http://dx.doi.org/10.1093/eurheartjsupp/suac099 |
Ejemplares similares
-
Role of lipoprotein(a) in plaque progression
por: Ruscica, Massimiliano, et al.
Publicado: (2022) -
‘Use of lipid-lowering therapy: the guidelines, the drugs or the patient?’
por: Borghi, Claudio, et al.
Publicado: (2022) -
Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023) -
Polygenic risk score and age: an extra help in the cardiovascular prevention of the young?
por: Temporelli, Pier Luigi
Publicado: (2022) -
Surgical approach to combined mitral and tricuspid valve disease: good neighbourhood rules
por: Ascione, Guido, et al.
Publicado: (2022)